Drug Trial Radar · NCT06978985
Adult SMA Research and Clinical Hub
Last checked: Nov 20, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Jul 29, 2022
Primary completion
Apr 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Newcastle-upon-Tyne Hospitals NHS TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Newcastle University; John Walton Muscular Dystrophy Research Centre; Biogen; Hoffmann-La Roche
- First posted
- May 18, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Adult SMA REACH is a data collection study aiming to gain a better understanding of the impact of standards of care and new treatments on the natural history of Spinal Muscular Atrophy (SMA). This study is sponsored by The Newcastle upon Tyne Hospitals NHS Foundation Trust. Adult SMA REACH is funded by Biogen and Roche. Currently, there are three drug treatments available for SMA in the UK: Zolgensma, Nusinersen and Risdiplam. Zolgensma is the only approved drug - Nusinersen and Risdiplam are currently available as part of Managed Access Agreements (MAA).
Conditions
- Spinal Muscular Atrophy (SMA)
Interventions
RisdiplamDrug
Risdiplam
Nusinersen Injectable ProductDrug
Nusinersen
Primary outcomes
What the sponsor says the trial is designed to measure.
- World Health Organization (WHO) Motor MilestonesTime frame: Baseline (at treatment initiation) and 6 monthly through study completion
- Revised Upper Limb Module (RULM)Time frame: Baseline (at treatment initiation) and 6 monthly through study completion
- 6 Minute Walk Test (6MWT)Time frame: Baseline (at treatment initiation) and 6 monthly through study completion
- The Hammersmith Functional Motor Scale Expanded (HFMSE)Time frame: Baseline (at treatment initiation) and 6 monthly through study completion
- The Egen classification 2 (EK2) scaleTime frame: Baseline (at treatment initiation) and 6 monthly through study completion
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom · Recruiting
North Bristol NHS Trust
Bristol, United Kingdom · Recruiting
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom · Recruiting
Cardiff and Vale University Health Board
Cardiff, United Kingdom · Recruiting
NHS Greater Glasgow and Clyde
Glasgow, United Kingdom · Recruiting
Bradford Teaching Hospitals NHS Foundation Trust
Leeds, United Kingdom · Recruiting
The Walton Centre NHS Foundation Trust
Liverpool, United Kingdom · Recruiting
University College London Hospitals NHS Foundation Trust
London, United Kingdom · Recruiting
King's College Hospital NHS Foundation Trust
London, United Kingdom · Recruiting
St George's University NHS Foundation Trust
London, United Kingdom · Recruiting
Newcastle-upon-Tyne Hospitals NHS Trust
Newcastle upon Tyne, United Kingdom · Recruiting
Nottingham University Hospitals Trust
Nottingham, United Kingdom · Recruiting
The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust
Oswestry, United Kingdom · Recruiting
Oxford University Hospitals Trust
Oxford, United Kingdom · Recruiting
The Northern Care Alliance NHS Foundation Trust
Salford, United Kingdom · Recruiting
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom · Recruiting
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom · Recruiting
South West Wales Neuromuscular Service in Swansea
Swansea, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.